Rebus Holdings, Inc. is dedicated to pioneering highly targeted therapies for oncology. Its flagship investigational product, RT-AR001, operates as an adenosine receptor antagonist. This compound, when administered directly into cancerous growths, is engineered to diminish tumor invasion and improve therapeutic efficacy. The corporation was established in 2003 and maintains its headquarters in Westlake Village, California.
—
Rebus Holdings, Inc. is dedicated to pioneering highly targeted therapies for oncology. Its flagship investigational product, RT-AR001, operates as an adenosine receptor antagonist. This compound, when administered directly into cancerous growths, is engineered to diminish tumor invasion and improve therapeutic efficacy. The corporation was established in 2003 and maintains its headquarters in Westlake Village, California.
—
Daily adjusted close
Rebus Holdings, Inc. is dedicated to pioneering highly targeted therapies for oncology. Its flagship investigational product, RT-AR001, operates as an adenosine receptor antagonist. This compound, when administered directly into cancerous growths, is engineered to diminish tumor invasion and improve therapeutic efficacy. The corporation was established in 2003 and maintains its headquarters in Westlake Village, California.